Do male lymphoma survivors have impaired sexual function?

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 6019-6026

  Kiserud, Cecilie E ^a   Schover, Leslie R ^a   Dahl, Alv A ^a   Fosså, Alexander ^a   Bjøro, Trine ^a   Loge, Jon Håvard ^a   Holte, Harald ^a   Yuan, Ying ^a   Fosså, Sophie D ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ADULT; AGING; ARTICLE; BLOOD SAMPLING; CANCER SURVIVOR; CLINICAL ASSESSMENT; CONTROLLED STUDY; EJACULATION; EMOTIONAL STRESS; FATIGUE; FOLLOW UP; HEALTH STATUS; HORMONE BLOOD LEVEL; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PENIS ERECTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SEXUAL FUNCTION; SEXUAL SATISFACTION; SHORT FORM 36; SOCIOECONOMICS; AGE DISTRIBUTION; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; HYPOGONADISM; METABOLISM; MIDDLE AGED; NORWAY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTOR; SATISFACTION; SEXUAL DYSFUNCTION; STATISTICAL MODEL; SURVIVOR; TIME; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EJACULATION; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; HYPOGONADISM; LINEAR MODELS; LUTEINIZING HORMONE; LYMPHOMA; MALE; MIDDLE AGED; NORWAY; PENILE ERECTION; PERSONAL SATISFACTION; QUESTIONNAIRES; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SURVIVORS; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 73349095062     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.2280     Document Type: Article

References (47)

1. Dahl AA, Bremnes R, Dahl O, et al: Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol 52:1438-1447, 2007
2. Schover LR, Fouladi RT, Warneke CL, et al: Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer 95:1773-1785, 2002
3. Schover LR: Sexuality and fertility after cancer. Hematology Am Soc Hematol Educ Program 523-527, 2005
4. Abrahamsen AF, Loge JH, Hannisdal E, et al: Socio-medical situation for long-term survivors of Hodgkin's disease: A survey of 459 patients treated at one institution. Eur J Cancer 34:1865-1870, 1998
5. Aksoy S, Harputluoglu H, Kilickap S, et al: Erectile dysfunction in successfully treated lymphoma patients. Support Care Cancer 16:291-297, 2008
6. Fobair P, Hoppe RT, Bloom J, et al: Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol 4:805-814, 1986
7. Jonker-Pool G, Hoekstra HJ, van Imhoff GW, et al: Male sexuality after cancer treatment: Needs for information and support - Testicular cancer compared to malignant lymphoma. Patient Educ Couns 52:143-150, 2004
8. Kornblith AB, Anderson J, Cella DF, et al: Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD. Cancer 70:2508-2516, 1992
9. Howell SJ, Radford JA, Ryder WD, et al: Testicular function after cytotoxic chemotherapy: Evidence of Leydig cell insufficiency. J Clin Oncol 17:1493-1498, 1999
10. Howell SJ, Shalet SM: Testicular function following chemotherapy. Hum Reprod Update 7:363-369, 2001
11. Lee SJ, Schover LR, Partridge AH, et al: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917-2931, 2006
12. Howell SJ, Radford JA, Smets EM, et al: Fatigue, sexual function and mood following treatment for haematological malignancy: The impact of mild Leydig cell dysfunction. Br J Cancer 82:789-793, 2000
13. Kiserud CE, Fossa A, Bjoro T, et al: Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer 100:455-463, 2009
14. Fugl-Meyer K, Fugl-Meyer AR: Sexual disabilities are not singularities. Int J Impot Res 14:487-493, 2002
15. Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States: Prevalence and predictors. JAMA 281:537-544, 1999
16. Lindau ST, Schumm LP, Laumann EO, et al: A study of sexuality and health among older adults in the United States. N Engl J Med 357:762-774, 2007
17. Nicolosi A, Laumann EO, Glasser DB, et al: Sexual behavior and sexual dysfunctions after age 40: The global study of sexual attitudes and behaviors. Urology 64:991-997, 2004
18. Nicolosi A, Buvat J, Glasser DB, et al: Sexual behaviour, sexual dysfunctions and related help seeking patterns in middle-aged and elderly Europeans: The global study of sexual attitudes and behaviors. World J Urol 24:423-428, 2006
19. O'Leary MP, Rhodes T, Girman CJ, et al: Distribution of the Brief Male Sexual Inventory in community men. Int J Impot Res 15:185-191, 2003
20. Guay A, Jacobson J: The relationship between testosterone levels, the metabolic syndrome (by two criteria), and insulin resistance in a population of men with organic erectile dysfunction. J Sex Med 4:1046-1055, 2007
21. Abrahamsen AF, Hannisdal E, Nome O, et al: Clinical stage I and II Hodgkin's disease: Long-term results of therapy without laparotomy: Experience at one institution. Ann Oncol 7:145-150, 1996
22. Blystad AK, Holte H, Kvaloy S, et al: High-dose therapy in patients with Hodgkin's disease: The use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. Bone Marrow Transplant 28:849-857, 2001
23. Evensen S, Brinch L, Tjønnfjord G, et al: Estimated 8-year survival of more than 40% in a population-based study of 79 adult patients with acute lymphoblastic leukaemia. Br J Haematol 88:88-93, 1994
24. Hagemeister FB, Tannir N, McLaughlin P, et al: MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5:556-561, 1987
25. Holte H, Mella O, Wist E, et al: ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease. Acta Oncol 35:73-80, 1996 (suppl 8)
26. Kiserud CE, Fossa A, Holte H, et al: Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer 96:1442-1449, 2007
27. Merk K, Idestrom K, Johansson B, et al: Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL. Eur J Haematol 46:33-37, 1991
28. Smeland S, Blystad AK, Kvaloy SO, et al: Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: A 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol 15:1072-1078, 2004
29. Sweetenham JW, Santini G, Qian W, et al: High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927-2936, 2001
30. Mykletun A, Dahl AA, O'Leary MP, et al: Assessment of male sexual function by the Brief Sexual Function Inventory. BJU Int 97:316-323, 2006
31. O'Leary MP, Fowler FJ, Lenderking WR, et al: A brief male sexual function inventory for urology. Urology 46:697-706, 1995
32. Chalder T, Berelowitz G, Pawlikowska T, et al: Development of a fatigue scale. J Psychosom Res 37:147-153, 1993
33. Mykletun A, Stordal E, Dahl AA: Hospital Anxiety and Depression (HAD) scale: Factor structure, item analyses and internal consistency in a large population. Br J Psychiatry 179:540-544, 2001
34. Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361-370, 1983
35. Ware JE Jr, Gandek B: Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 51:903-912, 1998
36. Cohen J: Statistical Power Analysis for the Behavioral Sciences. Mahwah, NJ, Lawrence Erlbaum Associates, 1988
37. Lipsey MW: Practical Meta-Analysis. Thousand Oaks, CA, Sage, 2001
38. Harman SM, Metter EJ, Tobin JD, et al: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 86:724-731, 2001
39. Suzuki R, Allen N, Appleby P, et al: Lifestyle factors and serum androgens among 636 middle aged men from seven countries in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 20:811-821, 2009
40. Ahn HS, Park CM, Lee SW: The clinical relevance of sex hormone levels and sexual activity in the ageing male. BJU Int 89:526-530, 2002
41. Svartberg J, Midtby M, Bonaa KH, et al: The associations of age, lifestyle factors and chronic disease with testosterone in men: The Tromso Study. Eur J Endocrinol 149:145-152, 2003
42. Yeap BB: Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res 21:24-36, 2009
43. Buvat J, Bou JG: Significance of hypogonadism in erectile dysfunction. World J Urol 24:657-667, 2006
44. Seruga B, Zhang H, Bernstein LJ, et al: Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887-899, 2008
45. Hammond CT, Beckjord EB, Arora NK, et al: Non-Hodgkin's lymphoma survivors' fertility and sexual function-related information needs. Fertil Steril 90:1256-1258, 2008
46. Tesauro GM, Rowland JH, Lustig C: Survivor-ship resources for post-treatment cancer survivors. Cancer Pract 10:277-283, 2002
47. Huyghe E, Sui D, Odensky E, et al: Needs assessment survey to justify establishing a reproductive health clinic at a comprehensive cancer center. J Sex Med 6:149-163, 2009